losing hair semaglutide and Loss: What Patients Need to Know How to Stop Semaglutide Hair

As of mid-2025, the FDA documented 605 adverse event reports specifically related to compounded semaglutide

There were no serious drug-related adverse events in SKYLIGHT 2, and only two (increased transaminases and abnormal liver function test) in SKYLIGHT 1

Secondly, to that point, is that people are looking at this potentially as a short-term solution

Kantreva K, Katsaounou P, Saltiki K, Trakada G, Ntali G, Stratigou T, et al

The genes affected by semaglutide included markers of inflammation and plaque stability that are associated with leukocyte recruitment [e.g., interleukin-1 (IL-1) receptor antagonist, IL-6, monocyte chemoattractant protein (CCL2), OPN], leukocyte adhesion [selectin E, vascular cell adhesion molecule-1 (VCAM1)], leukocyte extravasation and plaque stability (e.g., MMP3, MMP13, CCL2), and plaque rupture and hemorrhage (CD163)

This is different from the forced suppression of a stimulant